Related Experiment Video
Updated: Jan 13, 2026
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in
Yufang Yang1,2, Tao Liang1,2, Mingming Zhao3
1Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Background:
Efgartigimod, a neonatal Fc receptor (FcRn) blocker, is approved for generalized Myasthenia Gravis (gMG), but predictors of early response are unclear. Using minimal symptom expression (MSE) as the therapeutic target, we developed and externally validated a clinical model to predict early MSE response after starting efgartigimod. This efgartigimod-tailored model estimates the baseline probability of achieving early MSE and may assist in individualized treatment selection at therapy initiation.
Methods:
We retrospectively analyzed 118 adults with gMG treated at five tertiary centers in China (efgartigimod 10 mg/kg IV weekly ×4). MSE was defined as Myasthenia Gravis-Activities of Daily Living (MG-ADL) ≤ 1 sustained ≥ 4 weeks; early MSE response was achievement within 4 weeks of initiation. Patients were split into a derivation cohort (n = 64; three centers) and an external validation cohort (n = 54; two centers). Candidate predictors included demographics, baseline severity, and laboratory indices. Variables associated with early MSE in univariable analyses entered multivariable logistic regression to construct a nomogram. Discrimination (AUC-ROC), calibration (curves and Spiegelhalter Z-test), and clinical utility (decision curve analysis, DCA) were assessed, with bootstrap internal validation.
Results:
Early MSE response occurred in 26/64 derivation and 22/54 validation patients. Lower bulbar MG-ADL (OR 0.633, p = 0.040), higher FVC% (OR 1.042, p = 0.048), and lower IgG (OR 0.795, p = 0.036) independently predicted early MSE response. The nomogram showed strong discrimination-derivation AUC 0.869 (95% CI 0.797-0.941), bootstrap AUC 0.880 (0.806-0.954), and external AUC 0.839 (0.760-0.919)-and good calibration (Spiegelhalter Z: 1.03, p = 0.303; 0.94, p = 0.347; 1.17, p = 0.242). DCA indicated net benefit across thresholds 0.05-0.82, with validation curves mirroring derivation.
Conclusions:
A three-factor nomogram (bulbar MG-ADL, FVC%, and serum IgG) provides an efgartigimod-specific baseline estimate of early sustained-MSE response probability, which may help neurologists select appropriate candidates, counsel expected benefit, and tailor follow-up intensity or alternative escalation strategies.
Trail Registration:
Chinese Clinical Trial Registry (ChiCTR2500101971).
More Related Videos
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
09:18Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...